Ruboxistaurin

Ruboxistaurin

Clinical data
ATC code	none
Identifiers
IUPAC name (9S)-9-[(dimethylamino)methyl]-6,7,10,11-tetrahydro-9H,18H-5,21:12,17-di(metheno)dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecine-18,20-dione
CAS Number	169939-94-0 N
PubChem CID	153999
IUPHAR/BPS	5263
ChemSpider	135727 Y
UNII	721809WQCP
ChEMBL	CHEMBL91829 Y
Chemical and physical data
Formula	C28H28N4O3
Molar mass	468.546 g/mol
3D model (JSmol)	Interactive image
SMILES CN(C[C@]1([H])CCN2C=C(C(C(O)=NC3=O)=C3C(C4=CC=CC=C45)=CN5CCO1)C6=CC=CC=C62)C
InChI InChI=1S/C28H28N4O3/c1-30(2)15-18-11-12-31-16-21(19-7-3-5-9-23(19)31)25-26(28(34)29-27(25)33)22-17-32(13-14-35-18)24-10-6-4-8-20(22)24/h3-10,16-18H,11-15H2,1-2H3,(H,29,33,34)/t18-/m0/s1 Y Key:ZCBUQCWBWNUWSU-SFHVURJKSA-N Y
NY (what is this?)

Ruboxistaurin (proposed brand name Arxxant) is an investigational drug for diabetic retinopathy being investigated by Eli Lilly and Company. It is a member of the bisindolylmaleimide family.

On February 2006, Lilly submitted a New Drug Application for ruboxistaurin, and on August 18, 2006, Lilly received an "approvable" letter from the US FDA for ruboxistaurin, with a request for an additional clinical trial, which would take 5 years to complete.

Ruboxistaurin is an inhibitor of protein kinase C-beta.